ABSTRACT

Aim: To report outcome, toxicity, and survival of reirradition with hypofractionated radiotherapy concurrently temozolamide which is a novel approach to recurrent high- and low-grade glioma patients.Material and Methods: Twenty patients (8 males and 12 females; age between 26 and 70 years) with reccurent gliomas treated in our clinic were included in our study. The primary pathology was low grade in 12 patients and high grade in 8 patients. For recurrence hypofractionated radiotherapy, 350 cGy/fraction, totally 3500 cGy with concomitant temozolamide 75 mg/m2/day was applied.Results: Median OS was 55.42 months, median progression free survival was 38.26 months, and median survival from reirradiation was 9.3 months. Neither gender nor primary pathology had got effect on any of the survivals. Although being reoperated for recurrence did not affect progression free survival or survival after reirradiation, it has got statistically significant impact on overall survival. No severe toxicity was seen other than minor side effects. No interruption was needed so all of the patients were able to complete the treatment according to the scheduled plan.Conclusion: Reirradiation as hypofractionated radiotherapy with concomittant temozolamide is an effective, safe, and well-tolerated treatment for recurrent high and low glial tumors.

摘要

目的：报告大分割放疗联合替莫唑胺再放疗的结果、毒性和存活率，替莫唑胺是复发性高、低级别胶质瘤患者的一种新方法。材料和方法：20 名患者（8 名男性和 12 名女性；年龄在 26 至70 岁）在我们诊所治疗的复发性神经胶质瘤被纳入我们的研究。12 例患者的原发病理为低级别，8 例为高级别。对于复发性大分割放疗，350 cGy/次，共3500 cGy，同时应用替莫唑胺75 mg/m2/天。结果：中位OS为55.42个月，中位无进展生存期为38.26个月，再放疗中位生存期为9.3个月。性别和原发病理均未对任何存活产生影响。虽然因复发而再次手术并不影响无进展生存期或再放疗后的生存期，但对总生存期有统计学意义的影响。除了轻微的副作用外，没有观察到严重的毒性。无需中断，所有患者都能够按照预定计划完成治疗。结论：再放疗作为大分割放疗联合替莫唑胺是治疗复发性高、低神经胶质瘤的有效、安全和耐受性良好的治疗方法。